Lv65
2670 积分 2022-05-09 加入
Reduced doses of emicizumab achieve good efficacy: Results from a national‐wide multicentre real‐world study in China
1个月前
已完结
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study
1个月前
已完结
Fifty years of monoclonals: the past, present and future of antibody therapeutics
2个月前
已完结
Passive anti-amyloid β immunotherapy in Alzheimer's disease—opportunities and challenges
4个月前
已完结
Clinical promise of next-generation complement therapeutics
4个月前
已完结
Real-world Treatment Patterns Among Patients with Generalized Myasthenia Gravis (P6-11.027)
4个月前
已关闭
Subcutaneous drug delivery from nanoscale systems
6个月前
已完结
A guide to complement biology, pathology and therapeutic opportunity
6个月前
已完结
Complement in neurological disorders and emerging complement-targeted therapeutics
6个月前
已完结
Sequential immunotherapy: towards cures for autoimmunity
6个月前
已完结
皖公网安备34019202002308
